BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34518526)

  • 21. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.
    Rago F; DiMare MT; Elliott G; Ruddy DA; Sovath S; Kerr G; Bhang HC; Jagani Z
    Biochem Biophys Res Commun; 2019 Jan; 508(1):109-116. PubMed ID: 30527810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
    Lissanu Deribe Y; Sun Y; Terranova C; Khan F; Martinez-Ledesma J; Gay J; Gao G; Mullinax RA; Khor T; Feng N; Lin YH; Wu CC; Reyes C; Peng Q; Robinson F; Inoue A; Kochat V; Liu CG; Asara JM; Moran C; Muller F; Wang J; Fang B; Papadimitrakopoulou V; Wistuba II; Rai K; Marszalek J; Futreal PA
    Nat Med; 2018 Jul; 24(7):1047-1057. PubMed ID: 29892061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
    Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
    Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterozygous Mutations in SMARCA2 Reprogram the Enhancer Landscape by Global Retargeting of SMARCA4.
    Gao F; Elliott NJ; Ho J; Sharp A; Shokhirev MN; Hargreaves DC
    Mol Cell; 2019 Sep; 75(5):891-904.e7. PubMed ID: 31375262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
    Medina PP; Sanchez-Cespedes M
    Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
    Fernando TM; Piskol R; Bainer R; Sokol ES; Trabucco SE; Zhang Q; Trinh H; Maund S; Kschonsak M; Chaudhuri S; Modrusan Z; Januario T; Yauch RL
    Nat Commun; 2020 Nov; 11(1):5551. PubMed ID: 33144586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
    Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss.
    Zhu X; Fu Z; Chen SY; Ong D; Aceto G; Ho R; Steinberger J; Monast A; Pilon V; Li E; Ta M; Ching K; Adams BN; Negri GL; Choiniere L; Fu L; Pavlakis K; Pirrotte P; Avizonis DZ; Trent J; Weissman BE; Klein Geltink RI; Morin GB; Park M; Huntsman DG; Foulkes WD; Wang Y; Huang S
    Nat Commun; 2023 May; 14(1):2894. PubMed ID: 37210563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
    Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
    Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BAP1 regulates IP3R3-mediated Ca
    Bononi A; Giorgi C; Patergnani S; Larson D; Verbruggen K; Tanji M; Pellegrini L; Signorato V; Olivetto F; Pastorino S; Nasu M; Napolitano A; Gaudino G; Morris P; Sakamoto G; Ferris LK; Danese A; Raimondi A; Tacchetti C; Kuchay S; Pass HI; Affar EB; Yang H; Pinton P; Carbone M
    Nature; 2017 Jun; 546(7659):549-553. PubMed ID: 28614305
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Concepcion CP; Ma S; LaFave LM; Bhutkar A; Liu M; DeAngelo LP; Kim JY; Del Priore I; Schoenfeld AJ; Miller M; Kartha VK; Westcott PMK; Sánchez-Rivera FJ; Meli K; Gupta M; Bronson RT; Riely GJ; Rekhtman N; Rudin CM; Kim CF; Regev A; Buenrostro JD; Jacks T
    Cancer Discov; 2022 Feb; 12(2):562-585. PubMed ID: 34561242
    [No Abstract]   [Full Text] [Related]  

  • 32. SWI/SNF complex-deficient soft tissue neoplasms: An update.
    Schaefer IM; Hornick JL
    Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade.
    Romero OA; Vilarrubi A; Alburquerque-Bejar JJ; Gomez A; Andrades A; Trastulli D; Pros E; Setien F; Verdura S; Farré L; Martín-Tejera JF; Llabata P; Oaknin A; Saigi M; Piulats JM; Matias-Guiu X; Medina PP; Vidal A; Villanueva A; Sanchez-Cespedes M
    Nat Commun; 2021 Jul; 12(1):4319. PubMed ID: 34262032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
    Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
    Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial Inactivation of the Chromatin Remodelers SMARCA2 and SMARCA4 in Virus-Infected Cells by Caspase-Mediated Cleavage.
    Dudek AH; Pfaff F; Bolte H; Waguia Kontchou C; Schwemmle M
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29848589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
    Nguyen VT; Tessema M; Weissman BE
    Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
    Tian Y; Xu L; Li X; Li H; Zhao M
    Cancer Lett; 2023 Feb; 554():216022. PubMed ID: 36450331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
    Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
    Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
    Pottier N; Yang W; Assem M; Panetta JC; Pei D; Paugh SW; Cheng C; Den Boer ML; Relling MV; Pieters R; Evans WE; Cheok MH
    J Natl Cancer Inst; 2008 Dec; 100(24):1792-803. PubMed ID: 19066270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.